title: Mild cognitive impairment in Parkinson's disease.
abstract: Parkinson's disease (PD) traditionally has been defined by its characteristic motor hallmarks, but non-motor features such as cognitive impairment and dementia are increasingly recognized as part of PD. Mild cognitive impairment (MCI) is common in non-demented PD patients, occurring in about 20-50%. Frequency estimates and clinical features of mild cognitive impairment in PD (PD-MCI), however, vary across studies due to methodological differences and lack of uniform diagnostic criteria for PD-MCI. Overall, PD-MCI patients exhibit nonamnestic deficits in cognitive domains such as executive function, attention, and visuospatial function; however, the cognitive phenotype of PD-MCI is heterogeneous with some patients demonstrating greater amnestic deficits. PD-MCI patients, particularly those with posterior cortical profiles, may be at high risk for developing dementia. Various biomarkers studied in PD-MCI including cerebrospinal fluid, genetic analyses, and neuroimaging suggest that there may be distinct PD-MCI profiles. Future studies using uniform PD-MCI diagnostic criteria and incorporating biomarkers and longitudinal follow-up of PD-MCI cohorts are needed to understand PD-MCI as a transitional state between normal cognition and dementia.
authors.affiliation: Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University, Chicago, IL 60612, USA. jennifer_g_goldman@rush.edu
authors.forename: J G
authors.initials: JG
authors.lastname: Goldman
authors.forename: I
authors.initials: I
authors.lastname: Litvan
mesh_terms: D015415:Biomarkers / Q000134:cerebrospinal fluid; D060825:Cognitive Dysfunction / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D059906:Neuroimaging / Q000379:methods; D010300:Parkinson Disease / Q000150:complications*
chemical_list: D015415:Biomarkers